- Home
- FHTX vs AARD Comparison
FHTX vs AARD Comparison
Compare FHTX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- AARD
- Stock Information
- Founded
- FHTX 2015
- AARD 2017
- Country
- FHTX United States
- AARD United States
- Employees
- FHTX N/A
- AARD N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- FHTX Health Care
- AARD Health Care
- Exchange
- FHTX Nasdaq
- AARD Nasdaq
- Market Cap
- FHTX 278.1M
- AARD 242.9M
- IPO Year
- FHTX 2020
- AARD 2025
- Fundamental
- Price
- FHTX $5.06
- AARD $8.30
- Analyst Decision
- FHTX Strong Buy
- AARD Strong Buy
- Analyst Count
- FHTX 6
- AARD 5
- Target Price
- FHTX $11.33
- AARD $32.60
- AVG Volume (30 Days)
- FHTX 87.3K
- AARD 68.1K
- Earning Date
- FHTX 08-05-2025
- AARD 08-13-2025
- Dividend Yield
- FHTX N/A
- AARD N/A
- EPS Growth
- FHTX N/A
- AARD N/A
- EPS
- FHTX N/A
- AARD N/A
- Revenue
- FHTX $24,173,000.00
- AARD N/A
- Revenue This Year
- FHTX $43.75
- AARD N/A
- Revenue Next Year
- FHTX $1.27
- AARD N/A
- P/E Ratio
- FHTX N/A
- AARD N/A
- Revenue Growth
- FHTX N/A
- AARD N/A
- 52 Week Low
- FHTX $2.95
- AARD $4.88
- 52 Week High
- FHTX $10.25
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- FHTX 47.33
- AARD N/A
- Support Level
- FHTX $5.16
- AARD N/A
- Resistance Level
- FHTX $5.63
- AARD N/A
- Average True Range (ATR)
- FHTX 0.35
- AARD 0.00
- MACD
- FHTX 0.01
- AARD 0.00
- Stochastic Oscillator
- FHTX 38.83
- AARD 0.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.